STAT's obesity coverage hub collects ongoing reporting on GLP-1 weight-loss drugs such as Ozempic, Wegovy, and Mounjaro, spanning business, policy, and clinical developments. The page aggregates stories on pipeline drugs, Medicare access programs, industry competition between Novo Nordisk and Eli Lilly, and patient perspectives. It functions as a news roundup rather than a single-report article on one peptide.
The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.
No spam. Unsubscribe anytime.